The FDA has granted Fast Track Designation to Prescient Therapeutics' lead candidate PTX-100 for treating relapsed or refractory mycosis fungoides, the most common form of Cutaneous T-Cell Lymphoma.
Prescient Therapeutics receives FDA clearance for a Phase 2 trial of PTX-100 in relapsed and refractory cutaneous T-cell lymphomas, marking a crucial advancement.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.